Paxman AB
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has collaborated with the University of Huddersfield and the University of Leeds to develop a wearable medical cooling device; and the National University Hospital of … Read more
Paxman AB (PXMBF) - Net Assets
Latest net assets as of September 2025: $427.76 Million USD
Based on the latest financial reports, Paxman AB (PXMBF) has net assets worth $427.76 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($487.65 Million) and total liabilities ($59.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $427.76 Million |
| % of Total Assets | 87.72% |
| Annual Growth Rate | 25.87% |
| 5-Year Change | 1406.05% |
| 10-Year Change | N/A |
| Growth Volatility | 372.54 |
Paxman AB - Net Assets Trend (2017–2024)
This chart illustrates how Paxman AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Paxman AB (2017–2024)
The table below shows the annual net assets of Paxman AB from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $163.99 Million | +33.75% |
| 2023-12-31 | $122.62 Million | +7.37% |
| 2022-12-31 | $114.20 Million | -9.19% |
| 2021-12-31 | $125.75 Million | +1054.88% |
| 2020-12-31 | $10.89 Million | -61.61% |
| 2019-12-31 | $28.36 Million | +11.68% |
| 2018-12-31 | $25.39 Million | -22.50% |
| 2017-12-31 | $32.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Paxman AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4692100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $40.20 Million | 24.51% |
| Common Stock | $19.01 Million | 11.59% |
| Other Comprehensive Income | $104.78 Million | 63.90% |
| Other Components | $1.00K | 0.00% |
| Total Equity | $163.99 Million | 100.00% |
Paxman AB Competitors by Market Cap
The table below lists competitors of Paxman AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chino Commercial Bancorp
PINK:CCBC
|
$49.22 Million |
|
EVISO SPA
F:6Z8
|
$49.22 Million |
|
Everest Kanto Cylinder Limited
NSE:EKC
|
$49.22 Million |
|
BIT Mining Limited
NYSE:BTCM
|
$49.25 Million |
|
Tata Steel (Thailand) Public Company Limited
BK:TSTH
|
$49.19 Million |
|
Thai Coconut Public Company Limited
BK:COCOCO
|
$49.18 Million |
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
$49.18 Million |
|
VirTra Inc
NASDAQ:VTSI
|
$49.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Paxman AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 122,616,000 to 163,994,000, a change of 41,378,000 (33.7%).
- Net income of 40,196,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 9,511,000.
- Other factors decreased equity by 8,329,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $40.20 Million | +24.51% |
| Other Comprehensive Income | $9.51 Million | +5.8% |
| Other Changes | $-8.33 Million | -5.08% |
| Total Change | $- | 33.75% |
Book Value vs Market Value Analysis
This analysis compares Paxman AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.27x to 0.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $2.76 | $3.50 | x |
| 2018-12-31 | $1.59 | $3.50 | x |
| 2019-12-31 | $1.76 | $3.50 | x |
| 2020-12-31 | $0.68 | $3.50 | x |
| 2021-12-31 | $7.20 | $3.50 | x |
| 2022-12-31 | $6.01 | $3.50 | x |
| 2023-12-31 | $6.43 | $3.50 | x |
| 2024-12-31 | $8.59 | $3.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Paxman AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.51%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.89%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 1.39x
- Recent ROE (24.51%) is above the historical average (-25.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -20.52% | -21.46% | 0.69x | 1.39x | $-10.00 Million |
| 2018 | -27.96% | -12.24% | 1.04x | 2.19x | $-9.64 Million |
| 2019 | 9.72% | 3.23% | 1.00x | 3.00x | $-80.10K |
| 2020 | -176.20% | -24.58% | 1.01x | 7.07x | $-20.27 Million |
| 2021 | -10.16% | -13.28% | 0.58x | 1.32x | $-25.35 Million |
| 2022 | -9.04% | -6.59% | 0.90x | 1.52x | $-21.74 Million |
| 2023 | 6.79% | 3.78% | 1.32x | 1.36x | $-3.93 Million |
| 2024 | 24.51% | 15.89% | 1.11x | 1.39x | $23.80 Million |
Industry Comparison
This section compares Paxman AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Paxman AB (PXMBF) | $427.76 Million | -20.52% | 0.14x | $49.22 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |